FCCC LOGO Faculty Publications
Thomas C , Movva S
Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival
Onco Targets Ther. 2016 Sep;9 :5619-27
PMID: 27672333    PMCID: PMC5024770    URL: https://www.ncbi.nlm.nih.gov/pubmed/27672333
Back to previous list
Abstract
Patients diagnosed with metastatic soft-tissue sarcoma (STS) have a poor prognosis. Additionally, after failure of first-line therapy, there are relatively few treatment options from which to choose. The novel tubulin-binding drug, eribulin, with a unique mechanism of action from taxanes or vinca alkaloids, has shown clinical activity in several different types of cancers. Eribulin has been approved by the US Food and Drug Administration (FDA) for patients with metastatic breast cancer previously treated with an anthracycline or a taxane and has recently been FDA approved for patients with unresectable or metastatic liposarcoma who have failed a previous anthracycline regimen. Here, we review current standard treatments of STS, a background of eribulin, the studies that have propelled eribulin to FDA approval for liposarcoma, and future directions of the drug. The benefits of eribulin in STS are discussed in detail, especially with regard to the recent pivotal Phase III study comparing eribulin to dacarbazine for leiomyosarcoma and adipocytic sarcoma.
Notes
Thomas, Colin Movva, Sujana Review New Zealand Onco Targets Ther. 2016 Sep 9;9:5619-27. doi: 10.2147/OTT.S93517. eCollection 2016.